{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:15:08Z","timestamp":1771834508415,"version":"3.50.1"},"reference-count":10,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0266","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:19:46Z","timestamp":1753280386000},"source":"Crossref","is-referenced-by-count":0,"title":["Fingertip Fissures Associated with Ibrutinib in an Elderly Patient with Mantle Cell Lymphoma"],"prefix":"10.4274","author":[{"given":"\u015e\u00fcheda","family":"\u00c7akmak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Baysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seval","family":"Akp\u0131nar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/10428194.2013.803226","article-title":"Ibrutinib in chronic lymphocytic leukemia and B cell malignancies","volume":"55","author":"Brown","year":"2014","unstructured":"1. Brown JR. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma. 2014;55:263-269.","journal-title":"Leuk Lymphoma"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.3390\/ijms25063234","article-title":"Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms","volume":"25","author":"Mouhssine","year":"2024","unstructured":"2. Mouhssine S, Maher N, Matti BF, Alwan AF, Gaidano G. Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms. Int J Mol Sci. 2024;25:3234.","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"JO","year":"2022","unstructured":"3. Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022;386:2495-2506.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","unstructured":"4. Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97:638-656.","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","unstructured":"5. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507-516.","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40199-022-00444-w","article-title":"Efficacy and safety of ibrutinib in mantle cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Roufarshbaf","year":"2022","unstructured":"6. Roufarshbaf M, Javeri M, Akbari V, Matin PH, Farrokhi P, Sadeghi E, Heidari Z, Moghaddas A. Efficacy and safety of ibrutinib in mantle cell lymphoma: a systematic review and meta-analysis. Daru. 2022;30:367-378.","journal-title":"Daru"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","unstructured":"7. Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Dermatological toxicities of Bruton's tyrosine kinase inhibitors. Am J Clin Dermatol. 2020;21:799-812.","journal-title":"Am J Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Sollena P, Mannino M, Laurenti L, De Simone C, Peris K. Ibrutinib-associated palmo-plantar fissures in a patient with chronic lymphocytic leukaemia: a novel cutaneous adverse event. J Eur Acad Dermatol Venereol. 2019;33:e342-e344.","DOI":"10.1111\/jdv.15632"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","unstructured":"9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.","journal-title":"Clin Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jaad.2019.12.031","article-title":"Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events","volume":"88","author":"Singer","year":"2023","unstructured":"10. Singer S, Tan SY, Dewan AK, Davids M, LaCasce AS, Treon SP, LeBoeuf NR. Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2023;88:1271-1281.","journal-title":"J Am Acad Dermatol"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:45:08Z","timestamp":1771832708000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-49932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":10,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0266","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}